Preclinical News and Research

RSS

Virotherapy treatment kills prostate cancer cells

A new study appearing in The Prostate has found that certain measles virus vaccine strain derivatives, including a strain known as MV-CEA, may prove to be an effective treatment for patients with advanced prostate cancer.

21 Jan 2009

Biotech venture seeks West Nile virus treatment from antibodies in geese

Rich Glynn, a straight-talking entrepreneur from South Dakota, doesn't mince words when explaining why a partnership between his fledgling goose operation and the University of North Dakota is a match made in heaven.

21 Jan 2009

Ground-breaking test for spem quality

Scientists have developed a ground-breaking method for testing the quality of a sperm before it is used in IVF and increase the chances of conception.

19 Jan 2009

New understanding on how aging causes broken bones to heal slowly

Researchers have unraveled crucial details of how aging causes broken bones to heal slowly, or not at all, according to study results published today in the Journal of Bone and Mineral Research.

19 Jan 2009

Stem cells could be used for personalized cancer treatment

Using cancer cells from an ovarian cancer patient and human embryonic stem cells, Israeli researchers have created a cancerous tumor in a mouse that mimics the way the tumor would develop in the patient's body.

15 Jan 2009

New drug shows promise for phenylketonuria

PKU is described by scientists as an autosomal recessive genetic disease that is characterized by a deficiency in an enzyme called phenylalanine hydroxylase (PAH).

15 Jan 2009

Advaxis wins European patent case involving Lovaxin-C vaccine

The European Patent Court in Munich, Germany has ruled in favor of Advaxis Incorporated and reversed a patent challenge made by Anza Therapeutics, Inc., formerly Cerus Corp.

15 Jan 2009

Novel low-cost immunotherapy for cancer cells

Molecules of sugar sitting on the surface of cancer cells are keys to the development of a new vaccine aimed at both treating and stopping the spread of certain types of cancers called carcinomas, which include prostate, breast, ovarian and lung, among others.

8 Jan 2009

New nasal spray vaccine shown to be effective against botulism

A preclinical study found a new nasal spray vaccine to provide complete protection against a major botulism toxin, according to a study published today in the Nature journal Gene Therapy .

8 Jan 2009

New drugs have longer clinical development times despite faster FDA review

While the U.S. Food and Drug Administration Drug has quickened review and approval of new medicines, the complex nature of diseases for which new therapeutics are being developed has resulted in longer clinical development times, according to the Tufts Center for the Study of Drug Development.

8 Jan 2009

Osteotech starts trial for DuraTech BioRegeneration Matrix

Osteotech, Inc. announced today that it has initiated a pivotal clinical trial for its DuraTech BioRegeneration Matrix.

7 Jan 2009

Onyx Pharmaceuticals acquires license option on novel JAK2 inhibitors from S*BIO

Onyx Pharmaceuticals, Inc. has announced that it has acquired an option to license rights to SB1518, an orally available, potent, and selective inhibitor of Janus Kinase 2 (JAK2), and SB1578, also a JAK2 inhibitor, from S*BIO Pte Ltd based in Singapore.

6 Jan 2009

Phase III studies of EXPAREL (DepoBupivacaine) from Pacira complete enrollment

Pacira Pharmaceuticals, Inc., an acute care specialty pharmaceutical company, announced today that enrollment has been completed in two pivotal Phase III SIMPLE trials to evaluate the safety and efficacy of a single intraoperative administration of EXPAREL(TM) (DepoBupivacaine) for prolonged postoperative analgesia.

6 Jan 2009

Cylene Pharmaceuticals starts CX-4945 trial - first-in class inhibitor of CK2

Cylene Pharmaceuticals announced today that it has initiated a Phase I clinical trial of its oral CK2 protein kinase inhibitor, CX-4945, in patients with advanced solid tumors, Castleman's disease, or multiple myeloma.

5 Jan 2009

Ingredient in cough medicine could treat prostate cancer

A study published today in the December issue of the European medical journal Anticancer Research demonstrates that an ingredient used in a common cough suppressant may be useful in treating advanced prostate cancer.

22 Dec 2008

World-first technique used to repair an injured donor lung

For the first time in the world, transplant surgeons at Toronto General Hospital, University Health Network used a new technique to repair an injured donor lung that was unsuitable for transplant, and then successfully transplanted it into a patient.

21 Dec 2008

VistaGen, WARF sign license agreement for human embryonic stem cell technology

VistaGen Therapeutics and the Wisconsin Alumni Research Foundation (WARF) have signed a license for human embryonic stem cell patents for the development and commercialization of stem cell-based research tools.

18 Dec 2008

Neuralstem files IND for amyotrophic lateral sclerosis stem cell trial

Neuralstem, Inc. announced this morning that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a clinical trial to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

18 Dec 2008

Bolder BioTechnology awarded NIH grant to continue development of growth hormone product

Bolder BioTechnology, Inc. today announced that it has been awarded a $1.9 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH).

16 Dec 2008

New bone and tissue regeneration technique

Using stem cell lines not typically combined, researchers at Columbia University Medical Center have designed a new way to "grow" bone and other tissues.

15 Dec 2008